Science News

Outcomes and treatments of IB1 cervical cancers with high recurrence risk: A 13 years’ experience.

A new interesting article has been published in Cancer Radiother. 2018 Oct 19. pii: S1278-3218(18)30355-X. doi: 10.1016/j.canrad.2018.03.006. [Epub ahead of print] and titled:

Outcomes and treatments of IB1 cervical cancers with high recurrence risk: A 13 years’ experience.

Authors of this article are:

Espenel S, Garcia MA, Vallard A, Langrand-Escure J, Guy JB, Trone JC, Ben Mrad M, Chauleur C, de Laroche G, Moreno-Acosta P, Rancoule C, Magné N.

A summary of the article is shown below:

PURPOSE: The aim of the present study was to identify management strategies and outcomes of patients with stage IB1 cervical cancer with high recurrence risk.MATERIALS AND METHODS: Medical files of all consecutive patients treated between 2004 and 2017 with external beam radiotherapy and/or brachytherapy for IB1 cervical cancer, whatever the lymph node status, were retrospectively reviewed.RESULTS: Forty-two patients were included, with a median age of 49.8 years old. Median tumour size, estimated with the initial pelvic magnetic resonance imaging, was 26mm (interquartile range [IQR]=19.5-35). Histological types were mainly squamous cell carcinoma (59.5%) and adenocarcinoma (33.3%). Lymphovascular invasion was reported for 38.1% of patients. Pelvic lymph nodes were involved for eight patients (19.0%). Surgery was performed for 39 patients (92.9%). A neoadjuvant treatment was delivered for 20 patients (47.6%), an adjuvant treatment for 19 patients (45.2%) and an exclusive radiotherapy (with or without chemotherapy) followed by brachytherapy for three patients (7.1%). Pathologic complete response was achieved in 61.5% of patients. With a median follow-up of 5.8 years (IQR=2.6-9.4), five patients (11.9%) experienced a tumour relapse. The five-year disease-free survival was 79.5% (95% confident interval [CI]=66.9-94.4), the five-year overall survival was 87.8% (95% CI=77.2-99.8), and the five-year disease-specific survival was 94.2% (95% CI=86.7-100).CONCLUSION: In current clinical practice, tailored treatments are delivered, and seems to give correct therapeutic index. However, clinical trials are needed to standardise treatment according to patient characteristics and recurrence risk factors.Copyright © 2018 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as:

Brachytherapy;Cancer du col de l’utérus;Cervical cancer;Curiethérapie;IB1;Radiotherapy;Radiothérapie


Categories: Science News